



27 September 2022

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

technegas
ultralute

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

Cyclopharm Appoints Professor Greg King as a Non-Executive Director

The board of Cyclopharm Limited, (ASX:CYC), is pleased to announce the appointment of Professor Gregory King as a Non-Executive director, with the appointment effective immediately. Dr. King is a world-renowned respiratory physiologist who brings over 25 years' experience as a clinician, educator and researcher to the Cyclopharm board.

Dr. King is Professor of Respiratory Medicine at the Northern and Central Clinical Schools of the University of Sydney and a Practitioner. Greg is also the Staff Specialist in the Department of Respiratory Medicine at Royal North Shore Hospital, where he directs the asthma service and is the Medical Director of the Respiratory Investigation Unit, and the Research Leader of the Airway Physiology and Imaging Group at the Woolcock Institute of Medical Research. In addition, Dr. King supervises PhD and other postgraduate students at the University of Sydney

Dr. King has investigated the mechanics of airways disease in relation to clinical aspects of disease. His expertise includes complex measurements of airway and lung function, including the use of Cyclopharm's Technegas® in numerous research initiatives since 1997. He has a clinical and research interest in asthma, COPD and bronchiolitis in haemopoietic stem cell transplant recipients. His research is designed to better understand and manage airways diseases, with the ultimate objective of developing cures.

Dr. King is a member of the American Thoracic Society (ATS), Asia Pacific Society of Respiriology (APSR), European Respiratory Society (ERS), the American Physiological Society (APS) and Thoracic Society of Australia and New Zealand (TSANZ). He is Chair Elect, Respiratory Structure and Function Assembly, APSR, and maintains active participation in the activities of the TSANZ in terms of teaching, professional development and executive committee function.

Professor King was born in New Zealand and is a medical graduate of Otago University in New Zealand. He completed his PhD at Sydney University on airway closure in asthma and completed Postdoctoral Research Fellowships at Sydney University and at the Pulmonary Research Laboratory of the University of British Columbia in Vancouver.

David Heaney, Cyclopharm Chair said, *"I am pleased the Board has appointed Professor King as a Non-Executive director. Greg is a globally respected and highly credentialed expert in the field of Respiratory Medicine who will add significant value to the Cyclopharm Board."*

Greg King said, *"I am delighted to join the Board of Cyclopharm. I have extensive, firsthand experience with using Technegas® for lung imaging and can attest to Cyclopharm's leadership position in this field. My research into COPD and Asthma has demonstrated use cases for Technegas® beyond PE that I am keen to help develop alongside supporting the imminent roll out of Technegas® in the US."*

James McBrayer, Cyclopharm Managing Director, said, *“It is very exciting to have a world-renowned expert of Professor King’s standing join the Cyclopharm Board. Greg’s decades of clinical research into airways diseases, especially COPD and Asthma, will provide valuable insights to help drive our Beyond PE growth strategy, in particular, and Cyclopharm’s broader strategic goals.”*

[ENDS]

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please refer to our website at www.cyclopharm.com or contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas™ used in functional lung ventilation imaging.

Technegas™

The Technegas™ technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnace for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas™, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.